These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 14609583)

  • 21. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
    Andreasen N; Blennow K
    Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease].
    Smach MA; Charfeddine B; Lammouchi T; Dridi H; Ben Othman L; Bennamou S; Limem K
    Ann Biol Clin (Paris); 2008; 66(5):531-5. PubMed ID: 18957342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
    Shoji M
    Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
    Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
    J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormalities of tau-protein and beta-amyloid in brain ventricle cerebrospinal fluid.
    Talab R; Valis M; Rehak S; Krejsek J
    Neuro Endocrinol Lett; 2009; 30(5):647-51. PubMed ID: 20035270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Rusinek H; Li J; Tsui W; Saint Louis LA; Clark CM; Tarshish C; Li Y; Lair L; Javier E; Rich K; Lesbre P; Mosconi L; Reisberg B; Sadowski M; DeBernadis JF; Kerkman DJ; Hampel H; Wahlund LO; Davies P
    Neurobiol Aging; 2006 Mar; 27(3):394-401. PubMed ID: 16125823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Biological markers for Alzheimer disease].
    Tanaka T; Wada K; Yamamori H; Tanaka S; Kudo T; Takeda M
    Seishin Shinkeigaku Zasshi; 2003; 105(4):387-92. PubMed ID: 12806899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
    Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP
    Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
    Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
    Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
    Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
    Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.
    Brew BJ; Pemberton L; Blennow K; Wallin A; Hagberg L
    Neurology; 2005 Nov; 65(9):1490-2. PubMed ID: 16275845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.